Coherus BioSciences has announced plans for a round of financing worth an initial $200m by issuing convertible senior notes, to be used in part for “for opportunistic pipeline acquisitions or licenses, working capital, and other general corporate purposes, which may include other debt repayment in the future.”
The biosimilars player underlined it had not “entered into any agreements or commitments with respect to any material acquisitions or...




